Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PODOMOUNT-Basket study of BI 764198 in proteinuric kidney diseases
2025-523425-17-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 2, randomised, double-blind trial in proteinuric kidney disease comparing BI 764198 with Placebo (2 arms). Primary endpoint: Relative change from baseline to Week 20 in 24-hour UPCR. Planned start Jun 2026; status: authorised.
02
Drugs
apecotrep
03
Conditions
proteinuric kidney disease
Beyond the preview
Go deeper on 2025-523425-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523425-17-00.